A Covid vaccine that is a critical part of the effort to vaccinate the developing world, as well as the UK, has an efficacy of 90% overall, its manufacturers have said after trials in the US and Mexico.
The UK has ordered 60m doses of Novavax, which has manufacturing agreements in Britain. Novavax has signed an agreement to provide 1.1bn doses to Covax, the UN-led initiative to get vaccines to poorer countries. The Serum Institute of India is contracted to make 100m doses, but has been making vaccines only for India in recent months in response to the Covid crisis there.
Announcing the US trial results, Novavax said it would file
→ Continue reading at The Guardian – News